PDCD1 and cutaneous melanoma: To gain further insight into the relationship of IFN-γ and the cytolytic index in skin melanoma, we explored two IFN-γ signatures that were recently proposed to predict patient response to Pembrolizumab (anti-PD-1), the “IFN-γ” and the “expanded immune” signatures [30].